Observational studyNature communications2021
Microbiota-based markers predictive of development of Clostridioides difficile infection.
Observational study in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02896244 (AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
Who cites it
58 citing papers in PubMed.
- A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.Cell reports. Medicine · 2026Trial
- A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Microbiome-based therapeutics forGut microbes · 2026Review
- Clinical Predictors of Nose/Throat Bacteriome and Fungal Colonization in Skilled Nursing Facility Residents.The Journal of infectious diseases · 2026Article
- Gut microbiome features associated with vancomycin-resistant Enterococcus acquisition in intensive care unit patients.Annals of clinical microbiology and antimicrobials · 2026Article
- Saccharomyces cerevisiae 48338 Suppresses Antibiotic-Induced Clostridioides difficile Infection in a Murine Model.Probiotics and antimicrobial proteins · 2026Article
- Article
- The Gut Microbiome and Butyrate Differentiate Clostridioides difficile Colonization and Infection in Children.The Journal of infectious diseases · 2026Article
- Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026Review
- Deoxycholate induces proline provision from Escherichia coli to enhance Clostridioides difficile virulence.The ISME journal · 2026Article
- Long-Term Antibiotic-Driven Gut Microbiota Disruption Promotes ToxigenicInfection and drug resistance · 2026Article
- Article
- Core-shell ZIF-8@Au labels for high-sensitivity lateral flow assays via thiol-functionalization and seed-mediated growth.Mikrochimica acta · 2025Article
- Unravelling three-way interactions betweenJournal of medical microbiology · 2025Review
- Article
- Combination of mitomycin C and low-dose metronidazole synergistically againstAntimicrobial agents and chemotherapy · 2025Article
- metaGEENOME: an integrated framework for differential abundance analysis of microbiome data in cross-sectional and longitudinal studies.BMC bioinformatics · 2025Article
- Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.The Journal of infectious diseases · 2025Article
- Global, regional, and national burdens ofMicrobiology spectrum · 2025Article
- Genomic Characterization and Functional Evaluation ofFoods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-induced modulation of the intestinal microbiota can lead to Clostridioides difficile infection (CDI), which is associated with considerable morbidity, mortality, and healthcare-costs globally. Therefore, identification of markers predictive of CDI could substantially contribute to guiding therapy and decreasing the infection burden. Here, we analyze the intestinal microbiota of hospitalized patients at increased CDI risk in a prospective, 90-day cohort-study before and after antibiotic treatment and at diarrhea onset. We show that patients developing CDI already exhibit significantly lower diversity before antibiotic treatment and a distinct microbiota enriched in Enterococcus and depleted of Ruminococcus, Blautia, Prevotella and Bifidobacterium compared to non-CDI patients. We find that antibiotic treatment-induced dysbiosis is class-specific with beta-lactams further increasing enterococcal abundance. Our findings, validated in an independent prospective patient cohort developing CDI, can be exploited to enrich for high-risk patients in prospective clinical trials, and to develop predictive microbiota-based diagnostics for management of patients at risk for CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.